EARA has highlighted the issues that could affect the efficient transportation of animals and animal related products used for research if there is a no-deal Brexit.
The submission to the UK Parliament Science and Technology Committee inquiry on Brexit, Science and Innovation: preparations for a no-deal by the EARA Brexit Taskforce, examined the import and export to and from the UK, of purpose-bred research animals, biological samples from research animals (blood, tissues, organs, embryos), medical and pharmaceutical supplies, plus supplies of specialised animal feed and research diets.
EARA Executive Director, Kirk Leech said: “Our main concern is that any logistical problems with transport and processing times, arising from lack of preparation for a no-deal Brexit, will have a negative effect on scientific investigation and animal welfare.”
EARA’s Brexit Taskforce has made a submission to the UK Parliament Health and Social Care Committee inquiry concerning the animal science used to develop human and veterinary medicines.
Critical to the continuing success of the biomedical sector will be the timely and efficient import/export transport of purpose-bred research animals, biological samples and vaccines.
The submission also offers concrete proposals for avoiding delays in the movement of animals and related materials.
‘Without the ability to move research animals from one country, or continent, to another, or from a breeder or supplier, to a research institution, crucial scientific research to discover new treatments may be disrupted,’ said Kirk Leech, EARA Executive Director.
EARA Brexit Taskforce Briefing on the potential implications for animal science in the UK and EU stemming from Brexit
EARA has brought together a group of organisations under a Brexit Taskforce. The Taskforce is comprised of the following organisations – EARA, ABPI, AnimalHealth Europe, Charles River Laboratories, Covance, Ellegaard Göttingen Minipigs, Envigo, GSK, Marshall BIoResources, National Office of Animal Health, Understanding Animal Research and the Wellcome Sanger Institute.
The Task Force has produced this briefing which addresses both the complexities and possible opportunities for animal science in Europe stemming from Exit. Read the briefing here
The aim of this initiative is to allow the wider biomedical sector the opportunity to raise concerns with both the 27 (through EU engagement) and UK authorities on outstanding and unresolved issues over Brexit and animal science. If you have any questions about the briefing or believe that your organisation would benefit from joining the Task Force please contact us at email@example.com
The European Animal Research Association (EARA) has backed the UK government’s recent statements on its commitment to animal welfare.
The UK Parliament recently voted not to carry over Article 13 of the Lisbon treaty into UK law as part of Brexit legislation – Article 13 states that ‘since animals are sentient beings, [countries must] pay full regard to the welfare requirements of animals’. This was seen by opponents as an attempt to undermine current standards of animal welfare in the UK and led to a reaffirming of the UK position by the Prime Minister, Theresa May.
In Parliament she said: “The Animal Welfare Act 2006 provides protection for all animals capable of experiencing pain or suffering which are under the control of man. But I reaffirm to that we will be ensuring that we maintain and enhance our animal welfare standards when we leave the EU.”
Commenting on the controversy EARA Executive Director, Kirk Leech, said: “The current debate has more to do with political manoeuvring than animal welfare.The UK is among the countries with the highest animal welfare standards in Europe and we welcome the UK Government’s stated intention to continue to enhance this in future. Both the Animal Welfare Act and the Animals (Scientific Procedures) Act, 1986 are dedicated to protecting sentient animals.”